MILESTONE PHARMACEUTICALS IN
MISTNASDAQTrading Snapshot
- Day Range
- $0.81 – $0.83
- 52-Week Range
- $0.75 – $3.06
- Volume
- $3.26B
- Avg Volume
- $3.31B
- Shares Outstanding
- 124.5M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $559,000
- P/E Ratio
- -1.2
- P/S Ratio
- 43.6x
- EPS (TTM)
- $-0.61
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +34.8%
Why Investors Own MIST
- ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MILESTONE PHARMACEUTICALS IN
MIST
StockOtter · stockotter.spaceAbout MILESTONE PHARMACEUTICALS IN
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular m
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat R
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular m
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes
MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular me
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)